{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"20"}]}],"title":"Participants with any Treatment Emergent AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"5"}]}],"title":"Participants with any Serious AE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"21"}],"units":"Participants"}],"description":"Number of participants who experienced an adverse events (AEs) or a serious adverse event (SAE)","groups":[{"description":"Participants received 1 mg/kg E-602 monotherapy administered weekly via IV infusion.","id":"OG000","title":"E-602 1 mg/kg"},{"description":"Participants received 3 mg/kg E-602 monotherapy administered weekly via IV infusion.","id":"OG001","title":"E-602 3 mg/kg"},{"description":"Participants received 10 mg/kg E-602 monotherapy administered weekly via IV infusion.","id":"OG002","title":"E-602 10 mg/kg"},{"description":"Participants received 20 mg/kg E-602 monotherapy administered weekly via IV infusion.","id":"OG003","title":"E-602 20 mg/kg"},{"description":"Participants received 30 mg/kg E-602 monotherapy administered weekly via IV infusion.","id":"OG004","title":"E-602 30 mg/kg"},{"description":"Participants received 20 mg/kg E-602 monotherapy administered weekly via IV infusion. They also received 350 mg cemiplimab administered every 3 weeks via IV infusion.","id":"OG005","title":"E-602 20 mg/kg in Combination With Cemiplimab"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"15 Months","title":"Number of Participants Who Experienced AEs or SAEs","type":"PRIMARY","unitOfMeasure":"Participants"}